FALASCA, LAURA
FALASCA, LAURA
Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants
2022-01-01 Alonzi, T; Aiello, A; Repele, F; Falasca, L; Francalancia, M; Garbuglia, Ar; Delogu, G; Nicastri, E; Piacentini, M; Goletti, D
Cysteamine with in vitro antiviral activity and immunomodulatory effects has the potential to be a repurposing drug candidate for covid-19 therapy
2022-01-01 Alonzi, T; Aiello, A; Petrone, L; Fard, Sn; D'Eletto, M; Falasca, L; Nardacci, R; Rossin, F; Delogu, G; Castilletti, C; Capobianchi, Mr; Ippolito, G; Piacentini, M; Goletti, D
ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells
2012-09-01 Romagnoli, A; Etna, M; Giacomini, E; Pardini, M; Remoli, M; Corazzari, M; Falasca, L; Goletti, D; Gafa, V; Simeone, R; Delogu, G; Piacentini, M; Brosch, R; Fimia, G; Coccia, E
Human immunodeficiency virus-induced cell death in cytokine-treated macrophages can be prevented by compounds that inhibit late stages of viral replication
1996-06-01 Bergamini, A; Dini, L; Capozzi, M; Ghibelli, L; Placido, R; Faggioli, E; Salanitro, A; Buonanno, E; Cappannoli, L; Ventura, L; Cepparulo, M; Falasca, L; Rocchi, G
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.
2018-01-01 Piacentini, M; Baiocchini, A; Del Nonno, F; Melino, G; Barlev, N; Rossin, F; D'Eletto, M; Falasca, L
TG2 regulates the heat-shock response by the post-translational modification of HSF1.
2018-01-01 Rossin, F; Villella, V; D'Eletto, M; Farrace, M; Esposito, S; Ferrari, E; Monzani, R; Occhigrossi, L; Pagliarini, V; Sette, C; Cozza, G; Barlev, N; Falasca, L; Fimia, G; Kroemer, G; Raia, V; Maiuri, L; Piacentini, M
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection
2023-01-01 Lécuyer, D; Nardacci, R; Tannous, D; Gutierrez-Mateyron, E; Deva Nathan, A; Subra, F; Di Primio, C; Quaranta, P; Petit, V; Richetta, C; Mostefa-Kara, A; Del Nonno, F; Falasca, L; Marlin, R; Maisonnasse, P; Delahousse, J; Pascaud, J; Deprez, E; Naigeon, M; Chaput, N; Paci, A; Saada, V; Ghez, D; Mariette, X; Costa, M; Pistello, M; Allouch, A; Delelis, O; Piacentini, M; Le Grand, R; Perfettini, J
Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis
2015-01-01 Rossin, F; D'Eletto, M; Falasca, L; Sepe, S; Cocco, S; Fimia, Gm; Campanella, M; Mastroberardino, Pg; Farrace, Mg; Piacentini, M
Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis
2021-01-01 Occhigrossi, L; Rossin, F; D'Eletto, M; Farrace, M; Ciccosanti, F; Petrone, L; Sacchi, A; Nardacci, R; Falasca, L; Del Nonno, F; Palucci, I; Smirnov, E; Barlev, N; Agrati, C; Goletti, D; Delogu, G; Fimia, G; Piacentini, M
Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection
2018-03-01 Palucci, I; Matic, I; Falasca, L; Minerva, M; Maulucci, G; De Spirito, M; Petruccioli, E; Goletti, D; Rossin, F; Piacentini, M; Delogu, G
Transglutaminase type 2-dependent selective recruitment of proteins into exosomes under stressful cellular conditions.
2016-08-01 DIAZ HIDALGO, L; Altuntas, S; Rossin, F; D'Eletto, M; Marsella, C; Farrace, Mg; Falasca, L; Antonioli, M; Fimia, G; Piacentini, M
Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma
2023-10-28 Muccioli, S; Brillo, V; Varanita, T; Rossin, F; Zaltron, E; Velle, A; Alessio, G; Angi, B; Severin, F; Tosi, A; D’Eletto, M; Occhigrossi, L; Falasca, L; Checchetto, V; Ciaccio, R; Fascì, A; Chieregato, L; Rebelo, Ap; Giacomello, M; Rosato, A; Szabò, I; Romualdi, C; Piacentini, M; Leanza, L
Type 2 Transglutaminase, mitochondria and Huntington's disease: menage a trois
2014-11-01 Altuntas, S; D'Eletto, M; Rossin, F; Hidalgo, Ld; Farrace, Mg; Falasca, L; Piredda, L; Cocco, S; Mastroberardino, Pg; Piacentini, M; Campanella, M
ZFP750 affects the cutaneous barrier through regulating lipid metabolism
2023-01-01 Butera, A; Agostini, M; Cassandri, M; De Nicola, F; Fanciulli, M; D’Ambrosio, L; Falasca, L; Nardacci, R; Wang, L; Piacentini, M; Knight, Ra; Jia, W; Sun, Q; Shi, Y; Wang, Y; Candi, E; Melino, G
| Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
|---|---|---|---|---|
| 1-gen-2022 | Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants | Alonzi, T; Aiello, A; Repele, F; Falasca, L; Francalancia, M; Garbuglia, Ar; Delogu, G; Nicastri, E; Piacentini, M; Goletti, D | Articolo su rivista | |
| 1-gen-2022 | Cysteamine with in vitro antiviral activity and immunomodulatory effects has the potential to be a repurposing drug candidate for covid-19 therapy | Alonzi, T; Aiello, A; Petrone, L; Fard, Sn; D'Eletto, M; Falasca, L; Nardacci, R; Rossin, F; Delogu, G; Castilletti, C; Capobianchi, Mr; Ippolito, G; Piacentini, M; Goletti, D | Articolo su rivista | |
| 1-set-2012 | ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells | Romagnoli, A; Etna, M; Giacomini, E; Pardini, M; Remoli, M; Corazzari, M; Falasca, L; Goletti, D; Gafa, V; Simeone, R; Delogu, G; Piacentini, M; Brosch, R; Fimia, G; Coccia, E | Articolo su rivista | |
| 1-giu-1996 | Human immunodeficiency virus-induced cell death in cytokine-treated macrophages can be prevented by compounds that inhibit late stages of viral replication | Bergamini, A; Dini, L; Capozzi, M; Ghibelli, L; Placido, R; Faggioli, E; Salanitro, A; Buonanno, E; Cappannoli, L; Ventura, L; Cepparulo, M; Falasca, L; Rocchi, G | Articolo su rivista | |
| 1-gen-2018 | Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. | Piacentini, M; Baiocchini, A; Del Nonno, F; Melino, G; Barlev, N; Rossin, F; D'Eletto, M; Falasca, L | Articolo su rivista | |
| 1-gen-2018 | TG2 regulates the heat-shock response by the post-translational modification of HSF1. | Rossin, F; Villella, V; D'Eletto, M; Farrace, M; Esposito, S; Ferrari, E; Monzani, R; Occhigrossi, L; Pagliarini, V; Sette, C; Cozza, G; Barlev, N; Falasca, L; Fimia, G; Kroemer, G; Raia, V; Maiuri, L; Piacentini, M | Articolo su rivista | |
| 1-gen-2023 | The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection | Lécuyer, D; Nardacci, R; Tannous, D; Gutierrez-Mateyron, E; Deva Nathan, A; Subra, F; Di Primio, C; Quaranta, P; Petit, V; Richetta, C; Mostefa-Kara, A; Del Nonno, F; Falasca, L; Marlin, R; Maisonnasse, P; Delahousse, J; Pascaud, J; Deprez, E; Naigeon, M; Chaput, N; Paci, A; Saada, V; Ghez, D; Mariette, X; Costa, M; Pistello, M; Allouch, A; Delelis, O; Piacentini, M; Le Grand, R; Perfettini, J | Articolo su rivista | |
| 1-gen-2015 | Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis | Rossin, F; D'Eletto, M; Falasca, L; Sepe, S; Cocco, S; Fimia, Gm; Campanella, M; Mastroberardino, Pg; Farrace, Mg; Piacentini, M | Articolo su rivista | |
| 1-gen-2021 | Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis | Occhigrossi, L; Rossin, F; D'Eletto, M; Farrace, M; Ciccosanti, F; Petrone, L; Sacchi, A; Nardacci, R; Falasca, L; Del Nonno, F; Palucci, I; Smirnov, E; Barlev, N; Agrati, C; Goletti, D; Delogu, G; Fimia, G; Piacentini, M | Articolo su rivista | |
| 1-mar-2018 | Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection | Palucci, I; Matic, I; Falasca, L; Minerva, M; Maulucci, G; De Spirito, M; Petruccioli, E; Goletti, D; Rossin, F; Piacentini, M; Delogu, G | Articolo su rivista | |
| 1-ago-2016 | Transglutaminase type 2-dependent selective recruitment of proteins into exosomes under stressful cellular conditions. | DIAZ HIDALGO, L; Altuntas, S; Rossin, F; D'Eletto, M; Marsella, C; Farrace, Mg; Falasca, L; Antonioli, M; Fimia, G; Piacentini, M | Articolo su rivista | |
| 28-ott-2023 | Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma | Muccioli, S; Brillo, V; Varanita, T; Rossin, F; Zaltron, E; Velle, A; Alessio, G; Angi, B; Severin, F; Tosi, A; D’Eletto, M; Occhigrossi, L; Falasca, L; Checchetto, V; Ciaccio, R; Fascì, A; Chieregato, L; Rebelo, Ap; Giacomello, M; Rosato, A; Szabò, I; Romualdi, C; Piacentini, M; Leanza, L | Articolo su rivista | |
| 1-nov-2014 | Type 2 Transglutaminase, mitochondria and Huntington's disease: menage a trois | Altuntas, S; D'Eletto, M; Rossin, F; Hidalgo, Ld; Farrace, Mg; Falasca, L; Piredda, L; Cocco, S; Mastroberardino, Pg; Piacentini, M; Campanella, M | Articolo su rivista | |
| 1-gen-2023 | ZFP750 affects the cutaneous barrier through regulating lipid metabolism | Butera, A; Agostini, M; Cassandri, M; De Nicola, F; Fanciulli, M; D’Ambrosio, L; Falasca, L; Nardacci, R; Wang, L; Piacentini, M; Knight, Ra; Jia, W; Sun, Q; Shi, Y; Wang, Y; Candi, E; Melino, G | Articolo su rivista |